As biomarkers are important for precision-medicine-based targeted therapies in dementia, the need for blood-based biomarkers to complement the high cost and invasive CSF and PET markers of amyloid-β and Tau proteins are eagerly anticipated.56 The gene discussed is MAPT; the disease is dementia.